09/647586

			537 PS 0 PG	PIC U & UU I ZUUU	
TRAN		FINFOR FION DISCLOS inder 37 CFR 1.97(b) or 1.97(Docket No. RDID0063US	
In Re /	Application Of: E	cric Argirios KITAS, et al.			
Serial No. To Be Assigned		Filing Date October 2, 2000	Examiner To Be Assigned	Group Art Unit To Be Assigned	
Title:	NEW COMPOU	NDS FOR DNA-TRANSFECTION	N		
		Assistant Comm Washingt	Idress to: nissioner for Patents on, D.C. 20231		
1. 🛚	37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.				
		37 CI	FR 1.97(c)		
2. 🗆	The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:				
	1. a Final Action under 37 CFR 1.113, or				
	2. a Notice of Allowance under 37 CFR 1.311,				
	whichev	ver occurs first.			
	Also submitted herewith is:				
	☐ a certification as specified in 37 CFR 1.97(e);				
		OR			
		set forth in 37 CFR 1.17(p) for s CFR 1.97(c).	submission of an Information Dis	sclosure Statement	

Copyright 1996 Legalsoft P10A/REV01

TRANSMITTAL OF INFOR TION DISCLOSURE STATEME

(Under 37 CrR 1.97(b) or 1.97(c))

Docket No. RDID0063US

In Re Application Of:	Eric Argirios KITAS, et al.
-----------------------	-----------------------------

Serial No.

Filing Date

Examiner

Group Art Unit

To Be Assigned

October 2, 2000

To Be Assigned

To Be Assigned

NEW COMPOUNDS FOR DNA-TRANSFECTION

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of

is attached.

- The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0877 as described below. A duplicate copy of this sheet is enclosed.
 - Charge the amount of
 - X Credit any overpayment.
 - Charge any additional fee required. X

Certificate of Transmission by Facsimile*

l	I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.
	(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with the U.S. Postal Service as on first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.

Kenneth J. Waite, Reg. No. 45,189 **Roche Diagnostics Corporation**

9115 Hague Road, Bldg D

P.O. Box 50457

Indianapolis, IN 46250 Telephone: (317) 576-3104

Mail Via Express Mail No. EL315020591US

on October 2, 2000

Dated: October 2, 2000

CC:

09/647586

INFORMATION DISCLOSUR

SERIAL NO. RDID0063HS CONTROL OF THE PASSING TO 200 Eric Argirios KITA and al.					
FILING October 2, 2000	GROUP To Be Assigned				

(Use several sheets if nece U.S. PATENT DOCUMENTS FILING DATE SUBCLASS CLASS NAME *EXAMINER DATE DOCUMENT NUMBER IF APPROPRIATE INITIAL FOREIGN PATENT DOCUMENTS TRANSLATION SUBCLASS CLASS COUNTRY DOCUMENT NUMBER DATE YES NO 47/48 **A61K** 07/97 Europe EP0784984A2 (Including Author, Title, Date, Pertinent Pages, Etc.) OTHER DOCUMENTS Dempsey, Christopher E., "The Actions of Melittin on Membranes", Biochemica et Biophysica Acta, 1031 (1990) 143-161 Juvvadi, Padmaja et al, "Synthetic Melittin, Its Enantio, Retro, and Retroenantio Isomers, and Selected Chimeric Analogs: Their Antibacterial, Hemolytic, and Lipid Bilayer Action" Journal of the American Chemical Society Volume 118, Number 38, September 25, 1996, 8989-8997 **DATE CONSIDERED** EXAMINER

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOS	UF
(Use several sheets if n	nece. ()

ATTY DOCKET NO. RDID0063US SERIAL NO.

Rec'd PCT/PTC 02 0CT 2000 Eric Argirios KI GROUP

			October 2, 2000		2000	To Be Assigned				
	-			U.S.	PATENT D	OCUMENTS				
*EXAMINER			DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE	
INITIAL										
		 i								
										- ·
		_								
		_						<u> </u>		
	<u> </u>			FORE	IGN PATEN	IT DOCUMENTS		<u> </u>		
	<u> </u>	1		1	I I		CLASS	SUBCLASS	TRANS	LATION
		<u> </u>	DOCUMENT NUMBER	DATE	! 	COUNTRY	CEAGG	OGDOL/100	YES	NO
		<u> </u>								
								-	<u> </u>	
			OTHER DOCUME	NTS (Includir	ng Author,	Title, Date, Pertin	ent Pages, Etc.	Tuor of a -ti	of Mamma	ion Calle!!
		4	Legendre, J.Y. et al, "Dioleoylemelittin as a Novel Serum-Insensitive Reagent for Efficient Transfection of Mammalian Cells" Bioconjugate Chem. 1997, 8, 57-63							
		5	Legendre, Jean-Yves et al., "Short-Chain Phospholipids Enchance Amphipathic Peptide Medicated Gene Transfer" Biochemical and Biophysical Research Communications, Vol. 217, No. 1, December 5, 1995 179-185							
EXAMINE	R	<u> </u>	<u> </u>	<u> </u>		DATE CONSIDERED)			
*EYAMINI	ER: Init	hial if ro	ference considered, wheth	er or not citation is	s in conform	ance with MPEP 609; I	Draw line through c	itation if not in	conformance	and not

considered. Include copy of this form with next communication to applicant.